Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Congress Already Preparing For User Fee Bills

Executive Summary

Multiple congressional offices attended a briefing on GDUFA III with FDA and industry officials, suggesting plans for the must-pass bill already are in the works.

You may also be interested in...



US FDA Aims To Speed Communications On Cell And Gene Therapy Issues With Q&A Guidance

Advocates also call for reauthorization negotiations to be open to the public during meeting on the PDUFA VII commitment letter.

US GDUFA III Talks In Final Stages, Agreement Nearly Complete

Final commitment letter preparations now under way as revenue issues are resolved.

FDA Considers Incorporating Patient Input In Generic Drug Assessments

The popular patient-focused drug development model for new drugs might not fit for generics, in part because the affected patient groups would be much larger.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS144495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel